For our investors

February 17, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Read more

For our investors

February 17, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Read more

For our investors

February 17, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Read more

For our investors

February 17, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Read more

For our investors

February 17, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Read more

Our future growth and value generation is based on increasing revenues from our two marketed anti-infectives and our innovative pipeline

Investing in Basilea

  • Growing revenues: we continue to grow revenues from Cresemba and Zevtera, including launches in further markets
  • Building global brands: we strengthen and fully exploit the commercial potential from our marketed products. Our commercialization partnerships cover more than 100 countries
  • Solid cash position: allows us to explore opportunities to selectively expand our pipeline through in-licensing and internal research and development
  • Growth potential: we are focused on advancing and expanding our R&D portfolio to create sustainable shareholder value

Current presentation

Updated February 17, 2026

Download

 

 

 

 

 

Events and presentations

Feb 17. 2026
2025 Full-year results and publication of full-year report 2025

We will host a conference call and webcast at 4 p.m. (CET), to discuss the company’s financial and operating results for the full-year 2025 and to provide an outlook.

Webcast presentation

The live audio webcast of the results presentation can be followed here. Please note that there is no function to ask questions via webcast. For questions, please additionally dial-in via phone (see below).

To listen by phone and ask questions, please use the dial-in details below. To ensure prompt access, please call approximately five minutes prior to the scheduled start of the call.

+41 (0) 58 310 5000 (Switzerland, Europe and RoW)
+1 (1) 631 570 5613 (USA)
+44 (0) 207 107 0613 (UK)

The webcast, along with the presentation will be available online shortly after the event and accessible for three months.

Sep 22. 2025
Munich, Germany
Baader Investment Conference 2025
Sep 22. 2025
Zürich, Switzerland
HBM Biopharma Summit 2025
Sep 16. 2025
Stockholm, Sweden
Pareto Securities’ 16th Annual Healthcare Conference 2025
Sep 09. 2025 - Sep 10. 2025
New York City, United States
H.C. Wainwright 27th Annual Global Investment Conference

 

Archive

Annual General Meeting

Apr 15. 2026, 14:00 CEST
Congress Center Basel (CCB) in Basel, Switzerland
2026 Annual General Meeting of Shareholders

 

Archive

Analyst coverage

The analysts listed on this page have published reports or commentary on Basilea; there may be other analysts who have published reports or commentary that are not referenced here.  Please note that any opinions, estimates or forecasts regarding Basilea's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Basilea or its management.  Basilea does not by its reference on this website imply any endorsement of or concurrence with such information, conclusions or recommendations.

FIRMANALYST
Baader Helvea AGThomas Meyer
Calvine Partners LLPBrian White
Edison Investment Research Ltd.Jyoti Prakash
H. C. Wainwright & Co.Raghuram Selvaraju
Kepler CheuvreuxChristophe Dombu
Pareto Securities ABChien-Hsun Lee & Dan Akschuti
Zürcher KantonalbankLaurent Flamme

 

Share information

Convertible bonds

In July 2020, Basilea issued CHF 97.085 million convertible bonds due 2027 ("New Bonds", ISIN: CH0554992062; SSN: 55'499'206) and repurchased CHF 47.085 million of its CHF 200 million existing convertible bonds due 2022 ("Existing Bonds", ISIN: CH0305398148; SSN: 30'539'814). Through these transactions, the Company significantly improved its debt maturity structure. By December 2022, Basilea had repaid and cancelled the 2022 convertible bonds in full.

Sustainability (ESG)

At Basilea, we have performed a materiality analysis in 2023 that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model. These material topics form the basis of our ESG strategy. They will be key for the setting of goals and are at the core of our future ESG-related reporting. In 2024, we further developed our ESG strategy by defining KPIs for the individual focus topics. In 2025, a first sustainability report was developed in accordance with the GRI Standards and published as part of the full-year report 2025.

ESG report 2025

Key elements of Basilea's ESG strategy - update 2024

Key elements of Basilea's ESG strategy - initial release 2023

Corporate Governance